Navigation Links
Living Cell Technologies' Diabetes Clinical Trial Authorized by New Zealand Government
Date:6/24/2009

SYDNEY and AUCKLAND, New Zealand, June 24 /PRNewswire/ -- Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced that the New Zealand Minister of Health, the Honourable Tony Ryall, has authorized LCT's New Zealand Phase I/IIa clinical trial of DIABECELL(R) for insulin dependent diabetes.

The authorization confirms the conditions announced on 19 June 2009. One condition of the new authorization limits participation in the trial to patients with poorly controlled (brittle) diabetes. The remaining conditions are procedural rather than substantive in nature and LCT and the Middlemore Hospital clinical team conducting the trial, have requested the Regional Ethics Committee formally accept the changes required by the Minister.

LCT CEO Dr Paul Tan said: "We are pleased that the conditions have been finalized and LCT looks forward to commencing the trial within the next two months with the acceptance of the changes by the Ethics Committee."

Professor Bob Elliott, LCT Founder and Medical Director added: "The New Zealand diabetes trial is another major milestone for LCT. With two diabetes patients not requiring insulin following implants with encapsulated pig islet cells in our first study in Russia, we expect to see further benefit in more patients as we use higher doses of DIABECELL(R) in the New Zealand trial."

LCTs Phase I/IIa clinical trial in Russia started with a low dose of DIABECELL(R). In May 2009 LCT reported preliminary data showing sustained long term clinical benefit in patients treated with the DIABECELL(R) implant with no remarkable adverse events. Remarkably, two of seven patients given implants are now off insulin injections.

The New Zealand trial allows LCT to extend its Phase I/IIa clinical data with eight patients, four of whom are to receive double the initial dose used in Russia followed by four patients to receive triple the dose.

Dr John Baker, Clinical Director and Diabetes Physician at Middlemore Hospital, Auckland, who will be conducting the trial said, "There are many patients with poorly controlled diabetes who would qualify for this trial."

DIABECELL(R) is designed to normalize blood glucose levels in type 1 diabetes sufferers. DIABECELL(R) comprises encapsulated porcine insulin-producing cells which can be administered without the need to use immunosuppressive drugs.

Type 1 diabetes occurs when the body's own immune system destroys the insulin-producing cells of the pancreas (called beta cells). Five to 10 percent of the more than 200 million diabetics worldwide have insulin dependent type 1 diabetes. Type 1 diabetes is associated with kidney failure, blindness, nerve damage, life-threatening cardiovascular disease and limb amputations. Current treatment options include multiple daily injections of insulin.

For further information: www.lctglobal.com.

    CONTACT: Dr. Paul Tan
    Chief Executive Officer
    Mob: 021 608 784 (NZ)
    Tel: +64 9 276 2690
    ptan@lctglobal.com

    Mr John Cowan
    Finance & Administration Manager
    Tel: +64 9 276 2690
    jcowan@lctglobal.com

    Prof. Bob Elliott
    Medical Director
    Mob: +64 27 292 4177
    Tel:+64 9 276 2690
    relliott@lctglobal.com

    Paul Dekkers
    Investor and Media Relations
    Tel: +612 9237 2800
    pdekkers@bcg.com.au


'/>"/>
SOURCE Living Cell Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ADDAS Awareness Campaign Offers Resources and Education to Adults Living with AD/HD and Professionals Working With Them
2. Molecular probe paints cancer cells in living animals, Stanford researchers find
3. Scientists get first look at nanotubes inside living animals
4. Retirement Living TV Presents Sex, Drugs and Rock N Roll
5. CPF Living with IPF Patient Seminar to be Webcast Live October 13, 2007
6. Healthy Living Made Easy with New Diabetes Foodsmart e-Newsletter
7. National Energy Services Receives Repeat Orders From Golden Living and Cathedral Rock Skilled Nursing Facilities
8. Living Your Best Life: Adjusting Mind, Body and Spirit
9. How to Beat the High Cost of Living
10. Long Term Care Newsletter Debuts, Published by LTC Financial Partners; Advice on Living Better, Not Just Longer, With Financial Protection
11. A longer-living, healthier mouse that could hold clues to human aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... As health professionals work to improve their approach to ... is doing more than filling out a survey; in many cases health professionals and ... in health care and research on the importance of active engagement with patients and ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
Breaking Medicine Technology: